Ondine Biomedical Launches US Phase 3 Trial for Antimicrobial Therapy

Ondine Biomedical, Inc. ( (GB:OBI) ) has provided an update.

Ondine Biomedical Inc. has initiated the US Phase 3 clinical trial for its Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections, enrolling the first patient at Centennial Medical Center in Nashville. The trial, involving approximately 5,000 patients across 14 hospitals, aims to evaluate the efficacy of Ondine’s non-antibiotic nasal photodisinfection technology in reducing surgical site infections, compared to standard infection prevention methods. This milestone underscores Ondine’s commitment to providing healthcare professionals with innovative solutions that minimize drug resistance, with trial results anticipated in Autumn 2025.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has developed a pipeline of investigational products based on its proprietary technology, including nasal photodisinfection systems approved in Europe, Canada, and several other countries under the brand name Steriwave®. Ondine’s products aim to address various medical conditions and have received special designations from the FDA in the United States, where they are undergoing clinical trials for regulatory approval.

YTD Price Performance: -2.86%

Average Trading Volume: 463,209

Technical Sentiment Consensus Rating: Sell

Current Market Cap: £34.34M

Learn more about OBI stock on TipRanks’ Stock Analysis page.